Results 111 to 120 of about 1,043 (146)

Maribavir versus investigator assigned therapy: Exploring the exploratory

Transplant Infectious Disease, 2023
Madeleine R. Heldman, Ajit P. Limaye
openaire   +2 more sources

Ganciclovir/maribavir/valganciclovir

Reactions Weekly, 2021
openaire   +1 more source

Maribavir for the Management of Cytomegalovirus in Adult Transplant Recipients: A Review of the Literature and Practical Considerations

Annals of Pharmacotherapy, 2023
Hanna L Kleiboeker, Jillian L Descourouez, Didier A Mandelbrot   +2 more
exaly  

Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study

Blood, 2008
Drew J Winston, Jo-Anne H Young, Jared Klein   +2 more
exaly  

Efficacy and Safety of Maribavir Dosed at 100 mg Orally Twice Daily for the Prevention of Cytomegalovirus Disease in Liver Transplant Recipients: A Randomized, Double-Blind, Multicenter Controlled Trial

American Journal of Transplantation, 2012
F Saliba, E Blumberg, M Abouljoud
exaly  

Ganciclovir/Maribavir

Reactions Weekly
openaire   +2 more sources

Pharmacokinetics of Maribavir, a Novel Oral Anticytomegalovirus Agent, in Subjects With Varying Degrees of Renal Impairment

Journal of Clinical Pharmacology, 2007
Suzanne K Swan, Thomas C Marbury
exaly  

Effects of Maribavir on P‐Glycoprotein and CYP2D6 in Healthy Volunteers

Journal of Clinical Pharmacology, 2020
Ivy H Song, Katarina Ilić, Kenneth Lasseter   +2 more
exaly  

Maribavir/Valganciclovir

Reactions Weekly
openaire   +2 more sources

Maribavir

2010
openaire   +1 more source